Literature DB >> 29905391

Incomplete implementation of guideline-based stroke prevention therapy in sickle cell disease.

Alyssa M Schlenz1, Joannie Hayes1, Martina Mueller2,3, Shannon Phillips2, Robert J Adams4, Julie Kanter1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29905391      PMCID： PMC6168399          DOI： 10.1002/ajh.25163

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

1.  Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke.

Authors:  Douglas J Scothorn; Cynthia Price; Daniel Schwartz; Cindy Terrill; George R Buchanan; Wanda Shurney; Ingrid Sarniak; Robert Fallon; Jen-Yih Chu; Charles H Pegelow; Winfred Wang; James F Casella; Linda S Resar; Brian Berman; Thomas Adamkiewicz; Lewis L Hsu; Kwaku Ohene-Frempong; Kim Smith-Whitley; Donald Mahoney; J Paul Scott; Gerald M Woods; Masayo Watanabe; Michael R Debaun
Journal:  J Pediatr       Date:  2002-03       Impact factor: 4.406

2.  Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease.

Authors:  Robert J Adams; Donald Brambilla
Journal:  N Engl J Med       Date:  2005-12-29       Impact factor: 91.245

3.  Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.

Authors:  R J Adams; V C McKie; L Hsu; B Files; E Vichinsky; C Pegelow; M Abboud; D Gallagher; A Kutlar; F T Nichols; D R Bonds; D Brambilla
Journal:  N Engl J Med       Date:  1998-07-02       Impact factor: 91.245

Review 4.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

5.  Needs Assessment for Patients with Sickle Cell Disease in South Carolina, 2012.

Authors:  Alyssa M Schlenz; Andrea D Boan; Daniel T Lackland; Robert J Adams; Julie Kanter
Journal:  Public Health Rep       Date:  2016 Jan-Feb       Impact factor: 2.792

6.  Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.

Authors:  Russell E Ware; Barry R Davis; William H Schultz; R Clark Brown; Banu Aygun; Sharada Sarnaik; Isaac Odame; Beng Fuh; Alex George; William Owen; Lori Luchtman-Jones; Zora R Rogers; Lee Hilliard; Cynthia Gauger; Connie Piccone; Margaret T Lee; Janet L Kwiatkowski; Sherron Jackson; Scott T Miller; Carla Roberts; Matthew M Heeney; Theodosia A Kalfa; Stephen Nelson; Hamayun Imran; Kerri Nottage; Ofelia Alvarez; Melissa Rhodes; Alexis A Thompson; Jennifer A Rothman; Kathleen J Helton; Donna Roberts; Jamie Coleman; Melanie J Bonner; Abdullah Kutlar; Niren Patel; John Wood; Linda Piller; Peng Wei; Judy Luden; Nicole A Mortier; Susan E Stuber; Naomi L C Luban; Alan R Cohen; Sara Pressel; Robert J Adams
Journal:  Lancet       Date:  2015-12-06       Impact factor: 79.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.